Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
Phase 1 Completed
3 enrolled
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
Phase 1 Completed
35 enrolled
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Phase 1 Completed
50 enrolled
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Phase 1 Completed
50 enrolled
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Phase 1 Completed
34 enrolled 14 charts
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Phase 1 Completed
15 enrolled
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Phase 1 Completed
8 enrolled
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Phase 1 Completed
11 enrolled 16 charts
Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)
Phase 1 Completed
41 enrolled
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
Phase 1 Completed
14 enrolled
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Phase 1 Completed
45 enrolled 13 charts
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
Phase 1 Completed
154 enrolled
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Phase 1 Completed
18 enrolled
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
Phase 1 Completed
387 enrolled 2 FDA
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
Phase 1 Completed
43 enrolled
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Phase 1 Completed
70 enrolled
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Phase 1 Completed
132 enrolled
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
Phase 1 Completed
91 enrolled
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
Phase 1 Completed
34 enrolled
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Phase 1 Completed
16 enrolled
Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
Phase 1 Completed
18 enrolled
First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
Phase 1 Completed
229 enrolled
A Food Effect Study of LP-168 Tablets in Healthy Subjects
Phase 1 Completed
22 enrolled
A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)
Phase 1 Completed
17 enrolled
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Completed
35 enrolled
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
Phase 1 Completed
32 enrolled 30 charts
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
Phase 1 Completed
26 enrolled 10 charts
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Phase 1 Completed
232 enrolled
BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma
Phase 1 Completed
20 enrolled
BRiM
Phase 1 Completed
11 enrolled 20 charts
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
Phase 1 Completed
39 enrolled
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
Phase 1 Completed
37 enrolled
Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL
Phase 1 Completed
37 enrolled
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
Phase 1 Completed
32 enrolled
A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma
Phase 1 Completed
9 enrolled
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
Phase 1 Completed
183 enrolled 38 charts
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Phase 1 Completed
241 enrolled 31 charts
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
Phase 1 Completed
20 enrolled
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Phase 1 Completed
55 enrolled
Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL
Phase 1 Completed
20 enrolled
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
Phase 1 Completed
29 enrolled
Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma
Phase 1 Completed
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
Phase 1 Completed
16 enrolled
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
Phase 1 Completed
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 Completed
2 enrolled
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Phase 1 Completed
20 enrolled
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Phase 1 Completed
18 enrolled
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
Phase 1 Completed
26 enrolled
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
Phase 1 Completed
34 enrolled
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
Phase 1 Completed
20 enrolled